Overview

Phase 2a Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Status:
Terminated
Trial end date:
2021-01-28
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics (PK) of SPR719 generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Spero Therapeutics